Moleculin Biotech, Inc. 10-Q

ITEM 5. OTHER INFORMATION.    On August 8, 2022, the Compensation Committee of the Company’s Board of Directors approved the payment of a cash bonus to Mr. Walter Klemp of $375,000 payable upon the dosing of the first patient in the Company’s Phase 2 clinical trial of Annamycin for the treatment of soft tissue sarcoma lung metastases.   ITEM 6. EXHIBITS    Exhibit No.   Description       31.1*   Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002       31.2*   Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002       32.1*   Certification of Principal Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002       32.2*   Certification of Principal Accounting and Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002       101.INS*   Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)        101.SCH*   Inline XBRL Taxonomy Extension Schema Document       101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document       101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document       101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document       101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document       104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)   * Filed herewith.   19 Table of Contents   SIGNATURES   Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     MOLECULIN BIOTECH, INC.       Date: August 12, 2022 By: /s/ Walter V. Klemp     Walter V. Klemp,     Chief Executive Officer and Chairman (Principal Executive Officer)       Date: August 12, 2022 By: /s/ Jonathan P. Foster     Jonathan P. Foster,     Executive Vice President & Chief Financial Officer (Principal Financial and Accounting Officer)     20